These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8617583)

  • 1. Phase I trial of diaziquone (AZQ) plus GM-CSF.
    Hartmann LC; Ames MM; Reid JM; Richardson RL
    Invest New Drugs; 1995; 13(2):175-6. PubMed ID: 8617583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of high-dose diaziquone and autologous bone marrow transplantation: an Illinois Cancer Council study.
    Stiff PJ; McKenzie RS; Potempa LD; Albain K; Koch D; Braud E; Bansal VK; Weidner MK; Lanzotti VJ; Chun HG
    J Clin Oncol; 1991 Aug; 9(8):1487-94. PubMed ID: 2072148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.
    Berg SL; Balis FM; Zimm S; Murphy RF; Holcenberg J; Sato J; Reaman G; Steinherz P; Gillespie A; Doherty K
    J Clin Oncol; 1992 Jan; 10(1):143-8. PubMed ID: 1727916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
    Høst H; Joss R; Pinedo H; Bruntsch U; Cavalli F; Renard G; van Glabbeke M; Rozencweig M
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):295-8. PubMed ID: 6681775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
    Castleberry RP; Ragab AH; Steuber CP; Kamen B; Toledano S; Starling K; Norris D; Burger P; Krischer JP
    Invest New Drugs; 1990 Nov; 8(4):401-6. PubMed ID: 2084075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diaziquone and 2,2'-anhydro-arabinosyl-5-fluorocytosine for the treatment of children with relapsed or refractory acute nonlymphoblastic leukemia.
    Meyers PA; Tan CT; Steinherz PG; Redner A
    Cancer; 1989 Dec; 64(12):2416-9. PubMed ID: 2479459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent adenocarcinoma and adenosquamous carcinoma of the cervix. A Gynecologic Oncology Group study.
    Slayton RE; Blessing JA; Rettenmaier M; Ball H
    Invest New Drugs; 1989 Nov; 7(4):337-40. PubMed ID: 2599803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study.
    Slayton RE; Blessing JA; Clarke-Pearson D
    Invest New Drugs; 1991 Feb; 9(1):93-4. PubMed ID: 2026490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.
    Slayton RE; Blessing JA; Look K; Anderson B
    Invest New Drugs; 1991 May; 9(2):207-8. PubMed ID: 1874603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppies.
    Egorin MJ; Bellis EH; Salcman M; Collins JM; Spiegel JF; Bachur NR
    J Neurosurg; 1984 May; 60(5):1005-13. PubMed ID: 6716135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic effects of recombinant murine granulocyte-macrophage colony-stimulating factor on the peripheral blood and bone marrow.
    Ulich TR; del Castillo J; McNiece I; Watson L; Yin SM; Andresen J
    Am J Pathol; 1990 Aug; 137(2):369-76. PubMed ID: 1696784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
    Bachur NR; Collins JM; Kelley JA; Van Echo DA; Kaplan RS; Whitacre M
    Clin Pharmacol Ther; 1982 May; 31(5):650-5. PubMed ID: 7075113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
    Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
    J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial.
    Betteridge RF; Bosanquet AG; Gilby ED
    Eur J Cancer; 1990 Feb; 26(2):107-12. PubMed ID: 2138904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
    Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
    Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical evaluation of diaziquone in childhood cancer.
    Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
    Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.